Discordance between CD4 cell count and CD4 cell percentage: Implications for when to start antiretroviral therapy in HIV-1 infected children

AIDS

Volumn 24, Issue 8, 2010, Pages 1213-1217

  Dunn, David ^a  

^a NONE

Author keywords

CD4; Epidemiology; Natural history; Paediatrics; Prognosis

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; EUROPE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MONOTHERAPY; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCHOOL CHILD; UNITED STATES; WORLD HEALTH ORGANIZATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; UNITED STATES;

EID: 77951878739     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283389f41     Document Type: Article

References (18)

1. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. World Health Organisation; 2006.
2. PENTA guidelines for the use of antiretroviral therapy in pae-diatric infection-2008 draft revision. PENTA 2008. Available at http://www.pentatrials. org/guide08.pdf
3. Working group on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the use of anti-retroviral agents in pediatric HIV infection. February 23, 2009; pp 1-139. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.
4. HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20:1289-1294.
5. HIV Paediatric Prognostic Markers Collaborative Study. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monother-apy: a meta-analysis. Lancet 2003; 362:1605-1611.
6. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43 (No.RR-03):1-21.
7. GeboKA,GallantJE,KerulyJC,MooreRD.AbsoluteCD4vs.CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immun Defic Syndr 2004; 36:1028-1033.
8. Goicoechea M, Haubrich R. CD4 lymphocyte percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect Dis 2005; 192:945-947. (Pubitemid 41266788)
9. Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR. Absolute count and percentage of CD4R lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195:425-431. (Pubitemid 46146121)
10. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8:551-561. (Pubitemid 19116001)
11. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al., for the CHER study team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
12. DunnD, Woodburn P,Duong T, Peto J,Phillips A,GibbD,Porter K, for the HIV Paediatric Prognostic Markers Collaborative Study and the Concerted ActiononSero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration. CurrentCD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398-404. (Pubitemid 351263421)
13. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169:28-36. (Pubitemid 24976889)
14. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995; 73:17-24.
15. Paintsil E, Ghebremichael M, Romano S, Andiman WA. Absolute CD4R T-lymphocyte count as a surrogate marker for pediatric human immunodeficiency virus disease progression. Pediatr Infect Dis J 2008; 27:629-635.
16. Jeganathan S, Bansal M, Smith DE, Gold J. Comparison of different methodologies for CD4 estimation in a clinical setting. HIV Med 2008; 9:192-195. (Pubitemid 351467790)
17. Diabouga S, Chazallon C, Kazatchkine MD, Van de Perre P, Inwolev A, M'Boup S, et al. Successful implementation of a low-cost method for enumerating CD4R T Lymphocytes in resource limited settings: the ANRS 12-26 study. AIDS 2003; 17:2201-2208. (Pubitemid 37338893)
18. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008; 22:97-105.